Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Previously Published Works bannerUCLA

SOX7 is down-regulated in lung cancer.

  • Author(s): Hayano, Takahide
  • Garg, Manoj
  • Yin, Dong
  • Sudo, Makoto
  • Kawamata, Norihiko
  • Shi, Shuo
  • Chien, Wenwen
  • Ding, Ling-Wen
  • Leong, Geraldine
  • Mori, Seiichi
  • Xie, Dong
  • Tan, Patrick
  • Koeffler, H Phillip
  • et al.
Abstract

Background

SOX7 is a transcription factor belonging to the SOX family. Its role in lung cancer is unknown.

Methods

In this study, whole genomic copy number analysis was performed on a series of non-small cell lung cancer (NSCLC) cell lines and samples from individuals with epidermal growth factor receptor (EGFR) mutations using a SNP-Chip platform. SOX7 was measured in NSCLC samples and cell lines, and forced expressed in one of these lines.

Results

A notable surprise was that the numerous copy number (CN) changes observed in samples of Asian, non-smoking EGFR mutant NSCLC were nearly the same as those CN alterations seen in a large collection of NSCLC from The Cancer Genome Atlas which is presumably composed of predominantly Caucasians who often smoked. However, four regions had CN changes fairly unique to the Asian EGFR mutant group. We also examined CN changes in NSCLC lines. The SOX7 gene was homozygously deleted in one (HCC2935) of 10 NSCLC cell lines and heterozygously deleted in two other NSCLC lines. Expression of SOX7 was significantly downregulated in NSCLC cell lines (8/10, 80%) and a large collection of NSCLC samples compared to matched normal lung (57/62, 92%, p= 0.0006). Forced-expression of SOX7 in NSCLC cell lines markedly reduced their cell growth and enhanced their apoptosis.

Conclusion

These data suggest that SOX7 is a novel tumor suppressor gene silenced in the majority of NSCLC samples.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View